Epidemiology and Appropriateness of Antibiotic Prescribing in Severe Pneumonia After Lung Resection.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
07 2019
Historique:
received: 24 07 2018
revised: 15 01 2019
accepted: 29 01 2019
pubmed: 12 3 2019
medline: 8 10 2019
entrez: 12 3 2019
Statut: ppublish

Résumé

Postoperative pneumonia (POP) is a severe complication of major lung resection. The objective of this study was to describe the current epidemiology and appropriateness of antibiotic prescriptions in severe POP, 4 years after implementation of an antimicrobial stewardship program that was based on weekly multidisciplinary review of all antibiotic therapies. This study was a retrospective analysis of a prospectively collected database. It included all cases of severe POP occurring within 30 days after major lung resection of in a 1,500-bed hospital between 2013 and 2015. Criteria for severe POP were acute respiratory failure, severe sepsis, or a rapidly extensive pulmonary infiltrate. The study collected data on incidence, clinical outcomes, and microbiological analyses. Appropriateness of antibiotic prescribing was assessed by quality indicators previously validated in the literature. Over the study period, 1,555 patients underwent major lung surgery. Severe POP occurred in 91 patients (5.8%; confidence interval, 4.7%; 7.0%), with a mortality rate of 9.0% (8 of 91; confidence interval, 3.0%; 14.6%). In POP with positive microbiological results, the proportion of gram-negative bacteria other than Haemophilus was 76% (50 of 66 cases). All patients (91 of 91) had respiratory samples taken within 24 hours after the start of antibiotics; empiric therapy was concordant with the guideline in 80% (69 of 86), and it was switched to pathogen-directed therapy in 74% (46 of 62). In 71 of 91 patients (78%), the antibiotic duration was up to 7 days. This study reported a high proportion of gram-negative bacteria in severe POP. Four years after implementation of the program, quality indicators of antibiotic prescribing were all >70%. The rate of de-escalation to pathogen-directed therapy could be improved, however.

Sections du résumé

BACKGROUND
Postoperative pneumonia (POP) is a severe complication of major lung resection. The objective of this study was to describe the current epidemiology and appropriateness of antibiotic prescriptions in severe POP, 4 years after implementation of an antimicrobial stewardship program that was based on weekly multidisciplinary review of all antibiotic therapies.
METHODS
This study was a retrospective analysis of a prospectively collected database. It included all cases of severe POP occurring within 30 days after major lung resection of in a 1,500-bed hospital between 2013 and 2015. Criteria for severe POP were acute respiratory failure, severe sepsis, or a rapidly extensive pulmonary infiltrate. The study collected data on incidence, clinical outcomes, and microbiological analyses. Appropriateness of antibiotic prescribing was assessed by quality indicators previously validated in the literature.
RESULTS
Over the study period, 1,555 patients underwent major lung surgery. Severe POP occurred in 91 patients (5.8%; confidence interval, 4.7%; 7.0%), with a mortality rate of 9.0% (8 of 91; confidence interval, 3.0%; 14.6%). In POP with positive microbiological results, the proportion of gram-negative bacteria other than Haemophilus was 76% (50 of 66 cases). All patients (91 of 91) had respiratory samples taken within 24 hours after the start of antibiotics; empiric therapy was concordant with the guideline in 80% (69 of 86), and it was switched to pathogen-directed therapy in 74% (46 of 62). In 71 of 91 patients (78%), the antibiotic duration was up to 7 days.
CONCLUSIONS
This study reported a high proportion of gram-negative bacteria in severe POP. Four years after implementation of the program, quality indicators of antibiotic prescribing were all >70%. The rate of de-escalation to pathogen-directed therapy could be improved, however.

Identifiants

pubmed: 30853591
pii: S0003-4975(19)30269-3
doi: 10.1016/j.athoracsur.2019.01.072
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

196-202

Informations de copyright

Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Solen Kernéis (S)

Antimicrobial Stewardship Team, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Biostatistics, Biomathematics, Pharmacoepidemiology, and Infectious Diseases (B2PHI), Institut National de la Santé et de la Recherche Médicale (INSERM) 1181, Paris, France; B2PHI, Institut Pasteur, Paris, France; B2PHI, Versailles Saint-Quentin University, UMR 1181, Montigny-le-Bretonneux, France. Electronic address: solen.kerneis@aphp.fr.

Kim Blanc (K)

Department of Chest Disease and Respiratory Intensive Care, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Julien Caliez (J)

Department of Chest Disease and Respiratory Intensive Care, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Etienne Canouï (E)

Antimicrobial Stewardship Team, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Julien Loubinoux (J)

Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Bacteriology, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Rémy Gauzit (R)

Antimicrobial Stewardship Team, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France; Department of Anesthesiology and Critical Care, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Yên-Lan Nguyen (YL)

Department of Anesthesiology and Critical Care, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Anne Casetta (A)

Infection Control Team, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Aurélie Lefebvre (A)

Department of Chest Disease and Respiratory Intensive Care, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Jean-François Regnard (JF)

Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Thoracic Surgery, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Samir Bouam (S)

Department of Medical Information, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Marco Alifano (M)

Université Paris Descartes, Sorbonne Paris Cité, Paris, France; Department of Thoracic Surgery, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Antoine Rabbat (A)

Department of Chest Disease and Respiratory Intensive Care, AP-HP, Hôpitaux Universitaires Paris Centre-Site Cochin, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH